GlycoEra is focused on developing biologics to selectively target and degrade specific circulating proteins, particularly autoantibodies, that drive autoimmune diseases
GlycoEra is focused on developing biologics to selectively target and degrade specific circulating proteins, particularly autoantibodies, that drive autoimmune diseases. Their innovative approach aims to improve patient outcomes through precision immunology.
GlycoEra is focused on developing biologics to selectively target and degrade specific circulating proteins, particularly autoantibodies, that drive autoimmune diseases
GlycoEra is focused on developing biologics to selectively target and degrade specific circulating proteins, particularly autoantibodies, that drive autoimmune diseases. Their innovative approach aims to improve patient outcomes through precision immunology.